News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Press Release Issued Under The Early Warning System/Sale Of Shares Of Nymox Pharmaceutical (NYMX)


8/7/2014 7:35:45 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MONTREAL, Aug. 6, 2014 (GLOBE NEWSWIRE) -- This press release is being disseminated as required by the early warning requirements of applicable securities laws. Paul Averback MD announces today that he has sold in a private transaction for financial planning purposes 470,600 common shares of Nymox Pharmaceutical Corporation ("Nymox") for a total consideration of US $2,400,000 ($2,622,240 CDN). This sale represents 1.3% of the shares of Nymox issued and outstanding. As a result of this sale, Dr. Averback continues to own and control 10,931,448 shares of Nymox or approximately 31% of the shares of Nymox issued and outstanding. An additional 607,031 shares of Nymox (approximately 1.7%) are owned by a family trust of which Dr. Averback is a trustee. Dr. Averback is subject to the early warning requirements because he is a control person of Nymox by virtue of the fact that he owns more than 20% of the outstanding shares of Nymox. The sale relies on the prospectus exemption contained in Section 2.3 of Regulation 45-106 - Prospectus and Registration Exemptions. Nymox's common shares are listed on the NASDAQ Exchange under the symbol "NYMX".

To obtain a copy of the applicable securities report to be filed in connection with the matters set forth above, please contact:

Paul Averback
c/o Alain Fournier
Osler, Hoskin & Harcourt LLP
1000 De La Gauchetière West
Suite 2100
Montréal, Québec H3B 4W5
Tel : (514) 904-5390
Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES